CarbGeM is driving innovation in the life sciences through cutting-edge technologies, including regulatory-approved Software as a Medical Device (SaMD). The company empowers diagnostic support, research efficiency, and the standardization and automation of quality control. While addressing social challenges such as a shortage of skilled professionals and regional healthcare disparities, CarbGeM supports medical and industrial sectors by providing accurate and rapid results. Leveraging AI and digital platforms, the company fosters collaboration among healthcare professionals and researchers worldwide. CarbGeM is actively engaged in co-creating the future of medicine and science through open innovation with leading institutions across industry, academia, and government. The company has received numerous honors, including the Tokyo Social Innovation Tech Award 2024.
カーブジェン株式会社(本社：東京都渋谷区、代表取締役：中島正和、以下「当社」)は、ライフサイエンス・医療領域の研究者の皆様を対象としたAI導入サービス「AI for Science 伴走支援」の提供を本日より開始しま...
[画像1: https://prtimes.jp/i/100867/31/resize/d100867-31-412331a9d706b69500ce-2.png ] 独立行政法人国立病院機構 長崎医療センター（所在地：長崎県大村市、院長：高山 隼人、以下「長崎医療センター」）と...
[画像1: https://prtimes.jp/i/100867/30/resize/d100867-30-bfe309f686d706df1af1-1.png ] カーブジェン株式会社（本社：東京都渋谷区、代表取締役：中島正和、以下「当社」）は、AI開発・提供プラットフォーム...
[画像: https://prtimes.jp/i/100867/29/resize/d100867-29-a7770fed05fa23c23e1d-0.png ] カーブジェン株式会社（本社：東京都渋谷区、代表取締役：中島正和、以下「カーブジェン」）は、クラウドベースAI画像解...
[画像: https://prtimes.jp/i/100867/28/resize/d100867-28-aea9b90909b56defe5fc-1.png ] カーブジェン株式会社（本社：東京都渋谷区、代表取締役：中島正和、以下「カーブジェン」）は、実験進化（Experimental...
[画像: https://prtimes.jp/i/100867/27/resize/d100867-27-d180eb0ac26025cd1a57-1.png ] カーブジェン株式会社（本社：東京都渋谷区、代表取締役：中島正和、以下「カーブジェン」）は、微生物工学や合成生物学...
[画像: https://prtimes.jp/i/100867/25/resize/d100867-25-6f2c2364342cb1125dd4-0.png ] カーブジェン株式会社（本社：東京都渋谷区、代表取締役：中島正和、以下「当社」）は、ライフサイエンス領域向けクラウ...
[画像1: https://prtimes.jp/i/100867/24/resize/d100867-24-016487d2bcc2d36dce98-0.png ] （上記はイメージ図です。実際の「くま検知AIアラートシステム」とは異なります）カーブジェン株式会社（本社：東京都...
[画像1: https://prtimes.jp/i/100867/23/resize/d100867-23-f6a3e102efa281f9cf70-0.png ] カーブジェン株式会社（本社：東京都渋谷区、代表取締役：中島正和、以下「当社」）は、クラウドベースAI画像解析プラ...
[画像: https://prtimes.jp/i/100867/22/resize/d100867-22-e2f23cbb5070d0f153ac-0.png ] カーブジェン株式会社（本社：東京都渋谷区、代表取締役：中島正和、以下「カーブジェン」）は、ライフサイエンス分野の...
[画像: https://prtimes.jp/i/100867/21/resize/d100867-21-a796a84d5a018758b02f-1.png ] カーブジェン株式会社（代表取締役：中島正和、以下「当社」）は、ライフサイエンス領域のDX/AIソリューションで培った...
[画像: https://prtimes.jp/i/100867/20/resize/d100867-20-898d5c628e1d1f3a54d8-0.png ] カーブジェン株式会社（本社：東京都渋谷区、代表取締役：中島正和、以下「当社」）は、ライフサイエンス領域のDX/AIソ...
[画像: https://prtimes.jp/i/100867/19/resize/d100867-19-302b493c269adb0488e9-0.png ] カーブジェン株式会社（本社：東京都渋谷区、代表取締役：中島正和、以下「当社」）は、ライフサイエンス領域のDX/AIソ...
A Tokushima University-spinoff startup developing digital dental crown technology that treats teeth without grinding healthy enamel. By designing crowns that only replace necessary parts, it provides solutions to dental clinics, with adoption at 250 clinics nationwide, contributing to reduced patient costs and improved treatment precision.
A drug discovery venture tackling next-generation cancer treatment using marine-derived compounds that improve tumor hypoxia while minimizing side effects. Already commercialized as veterinary medicine, it supports the lives of both humans and pets.
Our company engages in the research and development, manufacturing, and sales of diagnostic test kits, primarily focused on in vitro diagnostic (IVD) products. In the field of infectious diseases, we provide rapid diagnostic kits for tropical infectious diseases such as dengue fever. In the pre-symptomatic healthcare field, we offer testing solutions—including genetic testing and microbiological testing—for individual and corporate sales, as well as for medical and research institutions. In addition, we collaborate not only within Japan but also with overseas bases and partners, including those in Thailand, and have established a product development and supply system that complies with regulatory requirements in each country.
【Neoself Platform for Clinical Diagnostics and Drug Development】 AOI Bio leverages a newly discovered mechanism, coined Neoself, underlying autoimmune diseases to provide diagnostic services and to develop novel therapeutics. AOI Bio. currently offers clinical testing for the B2GPI Neoself Antibody in patients with unexplained recurrent pregnancy or implantation failures. 【Bioinformatics Analysis Platform for Drug Discovery】 AOI Bio employs advanced computational methods to identify novel biomarkers and drug candidates. By utilizing industry-leading solutions, such as quantum-optimized allosteric pocket identification, AOI Bio. drives its groundbreaking drug development efforts forward.
